AI Startup BioinvestGPT Correctly Predicts Outcomes of Five of Six Major Drug Trials Before Results Announced

Copenhagen-based AI startup BioinvestGPT has demonstrated remarkable accuracy in forecasting clinical trial outcomes, correctly predicting the results of five of six major pharmaceutical studies before official announcements, according to analyses shared with Reuters. The achievement underscores both the potential and limitations of AI-driven drug development tools in an industry where trial failures routinely erase billions in market value.